Skip to main content

Table 2 Meta-Analysis of hOGG1 Ser326Cys Polymorphism and PCa

From: The hOGG1 Ser326Cys polymorphism and prostate cancer risk: a meta-analysis of 2584 cases and 3234 controls

Ser326Cys polymorphism Genetic model (No. of studies)

Sample size

Analysis

Test of association

P value for heterogeneity

P value for Egger's test

 

Case

Control

model

OR (95% CI)

P

  

Overall (8)

       

Cys/Cys vs Ser/Ser

1669

2155

R

1.06 (0.61-1.87)

0.83

< 0.00001

0.522

Cys/Cys vs Ser/Cys + Ser/Ser

2584

3234

R

1.00 (0.61-1.63)

0.99

< 0.0001

0.823

Cys/Cys + Ser/Cys vs Ser/Ser

2584

3234

R

1.12 (0.89-1.40)

0.33

0.001

0.082

Cys vs Ser

5168

6468

R

1.10 (0.88-1.37)

0.41

< 0.00001

0.158

Caucasian (3)

       

Cys/Cys vs Ser/Ser

306

292

R

1.92 (0.32-11.43)

0.47

< 0.0001

0.661

Cys/Cys vs Ser/Cys + Ser/Ser

498

556

R

1.60 (0.34-7.48)

0.55

0.0004

0.668

Cys/Cys + Ser/Cys vs Ser/Ser

498

556

R

1.50 (0.73-3.08)

0.27

0.0009

0.057

Cys vs Ser

996

1112

R

1.40 (0.70-2.78)

0.34

< 0.00001

0.251

Mixed (3)

       

Cys/Cys vs Ser/Ser

1080

1167

F

0.67 (0.50-0.90)

0.007

0.62

0.964

Cys/Cys vs Ser/Cys + Ser/Ser

1626

1766

F

0.68 (0.51-0.91)

0.008

0.69

0.920

Cys/Cys + Ser/Cys vs Ser/Ser

1626

1766

F

0.90 (0.78-1.03)

0.13

0.58

0.875

Cys vs Ser

3252

3532

F

0.88 (0.78-0.98)

0.02

0.54

0.982

  1. PCa = prostate cancer; OR = odds ratio; CI = confidence interval; vs = versus; R = random effect model; F = fixed effect model.